18β-glycyrrhetyl-3-O-sulfate would be a causative agent of licorice-induced pseudoaldosteronism.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
07 02 2019
Historique:
received: 09 11 2018
accepted: 21 12 2018
entrez: 9 2 2019
pubmed: 9 2 2019
medline: 20 8 2020
Statut: epublish

Résumé

Licorice-induced pseudoaldosteronism is a common adverse effect in traditional Japanese Kampo medicine, and 3-monoglucuronyl glycyrrhetinic acid (3MGA) was considered as a causative agent of it. Previously, we found 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate-30-glucuronide (1), one of the metabolites of glycyrrhizin (GL) in the urine of Eisai hyperbilirubinuria rats (EHBRs) treated with glycyrrhetinic acid (GA), and suggested that it is also a possible causative agent of pseudoaldosteronism. The discovery of 1 also suggested that there might be other metabolites of GA as causal candidates. In this study, we found 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate (2) and 18β-glycyrrhetyl-3-O-sulfate (3) in EHBRs' urine. 2 and 3 more strongly inhibited rat type 2 11β-hydroxysteroid dehydrogenase than 1 did in vitro. When EHBRs were orally treated with GA, GA and 1-3 in plasma and 1-3 in urine were detected; the levels of 3MGA were quite low. 2 and 3 were shown to be the substrates of organic anion transporter (OAT) 1 and OAT3. In the plasma of a patient suffering from pseudoaldosteronism with rhabdomyolysis due to licorice, we found 8.6 µM of 3, 1.3 µM of GA, and 87 nM of 2, but 1, GL, and 3MGA were not detected. These findings suggest that 18β-glycyrrhetyl-3-O-sulfate (3) is an alternative causative agent of pseudoaldosteronism, rather than 3MGA and 1.

Identifiants

pubmed: 30733510
doi: 10.1038/s41598-018-38182-2
pii: 10.1038/s41598-018-38182-2
pmc: PMC6367500
doi:

Substances chimiques

Glycyrrhizic Acid 6FO62043WK
11-beta-Hydroxysteroid Dehydrogenase Type 2 EC 1.1.1.146

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1587

Références

Eur J Endocrinol. 2000 Feb;142(2):200-7
pubmed: 10664531
J Agric Food Chem. 2000 Dec;48(12):6044-7
pubmed: 11312777
Drug Metab Rev. 2001 May;33(2):125-47
pubmed: 11495500
Analyst. 2001 Aug;126(8):1372-6
pubmed: 11534608
Yakugaku Zasshi. 2006 Oct;126(10):973-8
pubmed: 17016026
Life Sci. 2007 Apr 3;80(17):1545-52
pubmed: 17331546
Drug Metab Dispos. 2008 Jul;36(7):1438-43
pubmed: 18362159
Drug Metab Pharmacokinet. 2008;23(3):175-80
pubmed: 18574321
Mol Cell Endocrinol. 2012 Mar 24;350(2):168-86
pubmed: 21820034
J Pharmacol Exp Ther. 2012 Aug;342(2):297-304
pubmed: 22543032
Phytochem Anal. 2013 Nov-Dec;24(6):645-53
pubmed: 23761269
Endocrinology. 1989 Aug;125(2):1046-53
pubmed: 2752963
Lancet. 1987 Oct 10;2(8563):821-4
pubmed: 2889032
Sci Rep. 2018 Oct 22;8(1):15568
pubmed: 30348944
Chem Pharm Bull (Tokyo). 1986 Dec;34(12):4978-83
pubmed: 3568205
JAMA. 1968 Aug 12;205(7):492-6
pubmed: 5695305
J Clin Endocrinol Metab. 1995 Jun;80(6):1929-33
pubmed: 7775643
J Pharm Pharmacol. 1994 Feb;46(2):135-7
pubmed: 8021802
Aliment Pharmacol Ther. 1998 Mar;12(3):199-205
pubmed: 9570253
Biol Pharm Bull. 1998 Oct;21(10):1036-44
pubmed: 9821806

Auteurs

Kan'ichiro Ishiuchi (K)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Osamu Morinaga (O)

Department of Natural Medicines, Daiichi University of Pharmacy, 22-1 Tamagawamachi, Minami-ku, Fukuoka, Japan.

Takeshi Ohkita (T)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Chuanting Tian (C)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Asuka Hirasawa (A)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Miaki Mitamura (M)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Yasuhito Maki (Y)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Tsubasa Kondo (T)

Department of Natural Medicines, Daiichi University of Pharmacy, 22-1 Tamagawamachi, Minami-ku, Fukuoka, Japan.

Tomoya Yasujima (T)

Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Hiroaki Yuasa (H)

Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan.

Kiyoshi Minamizawa (K)

Department of Oriental Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Japan.

Takao Namiki (T)

Department of Japanese-Oriental (Kampo) Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan.

Toshiaki Makino (T)

Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Japan. makino@phar.nagoya-cu.ac.jp.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH